Tarpeyo (Budesonide) Patent Expiration, LOE Window & CMS Spending
Tarpeyo (Budesonide) by Calliditas Therapeutics Ab: FDA Orange Book LOE 2043-01-23, 5 AB generics, $64.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Calliditas Therapeutics Ab |
| FDA Application & Pathway | N215935 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2043-01-23 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $64.8M |
| 2024 Medicare Part D Spend | $38.3M |
| 2024 Medicaid Spend | $26.6M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 28.7% 2-yr change) |